Publications

5674 Results

Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized phase II trial in newly diagnosed chronic phase chronic myeloid leukemia

Authors
M Deininger;K Kopecky;J Radich;S Kamel-Reid;W Stock;E Paietta;P Emanuel;M Wadleigh;R Larson;J Lipton;M Slovak;F Appelbaum;B Druker
Journal / Conference
British Journal of Haematology 164(2):223-32;
Year
2014
Research Committee(s)
Leukemia
PMID
PMID24383843
PMC
PMC4127316
Study Number(s)
S0325

Four Different Regimens of Farnesyltransferase Inhibitor Tipifarnib in Older, Untreated Acute Myeloid Leukemia Patients: North American Intergroup Phase II study SWOG S0432

Authors
H Erba;M Othus;R Walter;M Kirschbaum;M Tallman;RA Larson;M Slovak;K Kopecky;H Gundacker;F Appelbaum
Journal / Conference
Leukemia Research 38(3):329-333;
Year
2014
Research Committee(s)
Leukemia
PMID
PMID24411921
PMC
PMC4247790
Study Number(s)
S0432

Effects of adjuvant exemestane versus anastrozole on bone mineral density in women with early breast cancer: a companion study to NCIC CTG MA.27

Authors
P Goss;D Hershman;A Cheung;J Ingle;S Khosla;V Stearns;H Chalchal;K Rowland;H Muss;H Linden;J Scher;CR Elliott;T Crnjevic;JA Chapman;L Shepherd
Journal / Conference
Lancet Oncology 15(4):474-482;
Year
2014
Research Committee(s)
Breast and Cancer Survivorship
PMID
PMID24636210
PMC
PMC4352316

A phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): SWOG study S0329

Authors
B Malhotra;J Moon;O Kucuk;JI Clark;S Urba;G Wolf;F Worden
Journal / Conference
Head & Neck 36(12):1712-1717
Year
2014
Research Committee(s)
Head and Neck
PMID
PMID24166832
PMC
PMC4640463
Study Number(s)
S0329

Declining rates of treatment-related mortality in patients with newly-diagnosed AML given "intense" induction regimens: a report from SWOG and MD Anderson

Authors
M Othus;H Kantarjian;S Petersdorf;F Ravandi;J Godwin;J Cortes;S Pierce;H Erba;S Faderl;F Appelbaum;E Estey
Journal / Conference
Leukemia 28(2):289-292;
Year
2014
Research Committee(s)
Leukemia
PMID
PMID23760400
PMC
PMC4457325
Study Number(s)
S0106, S0112, SWOG-8600, SWOG-9031, SWOG-9126, SWOG-9333, SWOG-9500, S9617, S9918

Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Authors
D Albanes;C Till;E Klein;P Goodman;A Mondul;S Weinstein;PR Taylor;H Parnes;JM Gaziano;X Song;NE Fleshner;F Meyskens;P Brown;IM Thompson
Journal / Conference
Cancer Prevention Research 27(9):886-895;
Year
2014
Research Committee(s)
Prevention, Screening, and and Surveillance
PMID
PMID24961880
PMC
PMC4408535
Study Number(s)
S0000

SWOG S0941: A phase II study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma

Authors
AB El-Khoueiry;C Rankin;AB Siegel;S Iqbal;I-Yeh Gong;KC Micetich;O Kayaleh;H Lenz;CD Blanke
Journal / Conference
British Journal of Cancer 110(4):882-887;
Year
2014
Research Committee(s)
Gastrointestinal
PMID
PMID24423918
PMC
PMC3929880
Study Number(s)
S0941

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia and myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905

Authors
T Prebet;Z Sun;ME Figueroa;R Ketterling;A Melnick;P Greenberg;M Juckett;M Smith;L Malick;E Paietta;M Czader;J Gabrilove;H Erba;S Gore;M Tallman
Journal / Conference
Journal of Clinical Oncology 32(12):1242-2348;
Year
2014
Research Committee(s)
Leukemia
PMID
PMID24663049
PMC
PMC3986386
Study Number(s)
E1905

Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup trial S0220

Authors
K Kernstine;J Moon;M Kraut;K Pisters;J Sonett;V Rusch;C Thomas;T Waddell;J Jett;A Lyss;S Keller;D Gandara
Journal / Conference
Annals of Thoracic Surgery 98(2):402-410;
Year
2014
Research Committee(s)
Lung
PMID
PMID24980603
PMC
PMC4122593
Study Number(s)
S0220

Germline genetic variants in ABCB1, ABCC1, and ALDH1A1 and risk of hematological and gastrointestinal toxicities in a SWOG phase III trial S0221 for breast cancer

Authors
S Yao;L Sucheston;H Zhao;G Zirpoli;S Liu;W Barlow;HCF Moore;GT Budd;DL Hershman;W Davis;GL Ciupak;JA Stewart;C Isaacs;T Hobday;M Salim;G Hortobagyi;JR Gralow;R Livingston;K Albain;D Hayes;CB Ambrosone
Journal / Conference
The Pharmacogenomic Journal 14(3):241-247;
Year
2014
Research Committee(s)
Breast
PMID
PMID23999597
PMC
PMC3940691
Study Number(s)
S0221